Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Federica Marmorino et al.|The Lancet Oncology|2022Cited by 268
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Chiara Cremolini, Michele Prisciandaro et al.|JCO Precision Oncology|2022Cited by 28
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Anguraj Sadanandam, Gift Nyamundanda et al.|JCO Precision Oncology|2020Cited by 7
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Chiara Cremolini, Mirella Giordano et al.|European Journal of Cancer|2021Cited by 7